User login

Enter your username and password here in order to log in on the website:
Choose language: English | Deutsch

Infront up-to-date–
news, dates, events

News

Events

Title
Date
Location
Category
FIX EMEA Trading Conference 2020
18.09.2020
London
Exhibitions and Congresses

The EMEA Trading Conferenceis Europe’s largest one-day electronic trading event. The event will cover the most pressing issues facing the institutional trading community and provide a neutral platform for buy-side, sell-side, exchanges, vendors and regulators to share their ideas on how the community can continue to collaborate. Designed to appeal to all asset classes, the agenda will maintain a great balance of topics across multiple asset classes.

The event will be held virtually. Further information will follow shortly.

11th AM Tech Day
13.10.2020
Paris
Exhibitions and Congresses

AM TECH DAY is the European market event dedicated to the impact of technological innovation on the asset management industry, gathering asset managers, wealth managers, asset owners, insurers and FinTechs. For its 11th year, the event will be held on 13 October at the Palais Brongniart, Paris.

The health crisis has made it more vital than ever to communicate, talk and work online, effectively boosting the value of all tools that can do this in a fast and secure way. It has also spurred their adoption throughout the asset management industry with the early adopters effectively providing a stress test for the sector.

At the same time, technologies continue to improve, giving professional investors a better handle on the key issues affecting sustainable development and helping them adopt best practice in transparency, equity and security.


Now more than ever, the asset management industry has the means and the opportunity to reinvent itself.
 

Meet Infront there: Palais Brongniart, 16 Place de la Bourse, at 10:00.

19th COPS Usertreff
22.10.2020
Rust
Exhibitions and Congresses

As in previous years, COPS invites to their annual COPS user meeting this year from 22 to 23 October 2020 at the Seehotel Rust in Rust on Neusiedlersee.

The customers can expect a versatile and varied program, ranging from innovations in software solutions, successful project reports to practical application examples.

As a strategic partner, COPS gives us the opportunity to present our company and our solutions and show-case the cooperation with COPS.

On site, our colleagues Catherine Hanek, Achim Beisswenger and Sebastian Ullrich will be available for a lively exchange of ideas.

You can find further information here...

SIPUGday 2020
27.10.2020
Zurich
Exhibitions and Congresses

The SIPUGday focuses since the start on market data and related technologies, services and products in the front, back and middle office. Regulations and their impact on data are also a topic for our audience.

Infront and vwd will be represented on site by Ivo Bieri, Managing Director Switzerland. He will be happy to inform you about the advantages for you of the merger of the two companies in the future. We look forward to a lively exchange with you!


Date
October 27, 2020
 

Place
Marriott Hotel,
Neumühlequai 42
8006 Zurich

Read more...

DKF 2020, 10. D-A-CH Kongress für Finanzinformationen
02.12.2020
Munich
Exhibitions and Congresses

We will again be represented at the DKF this year and look forward to your visit to our stand.

Further information will be available here soon or on the official DKF 2020 website.

Quantalys Inside 2020
18.12.2020
Paris
Exhibitions and Congresses

Further information will be available shortly here or under Quantalys Inside 2020.

 Latest news on markets, economy and companies

Newsroom

Business Wire

Mynewsdesk

GlobeNewswire

11.09.2019 GlobeNewswire: Janssen reports new head-to-head Phase 3 study data show ponesimod superiority versus Aubagio (teriflunomide) 14 mg in adults with relapsing multiple sclerosis

Janssen reports new head-to-head Phase 3 study data show ponesimod superiority

versus Aubagio (teriflunomide) 14 mg in adults with relapsing multiple

sclerosis

 

• OPTIMUM Phase 3 study data presented for the first time during oral

presentation at the 35th Congress of The European Committee for Treatment and

Research in Multiple Sclerosis

 

 

• Idorsia Pharmaceuticals Ltd, J&J and Actelion Pharmaceuticals Ltd have

a Revenue Sharing Agreement in respect to ponesimod

 

Allschwil, Switzerland – September 11, 2019

Idorsia Ltd (SIX: IDIA) today informed that the Janssen Pharmaceutical

Companies of Johnson & Johnson announced the results from the Phase 3 OPTIMUM

study for ponesimod, an investigational selective S1P 1 receptor modulator,

showing superior efficacy on the primary endpoint and most secondary endpoints

compared to Aubagio ® (teriflunomide)* 14 mg in adults with relapsing multiple

sclerosis (MS).

 

For further details please read the full announcement available here:

 

www.janssen.com/new-head-head-phase-3-study-data-show-ponesimod-superiority-versus-aubagio-teriflunomide-14-mg

 

 

About the Revenue Sharing Agreement

Idorsia Pharmaceuticals Ltd, J&J and Actelion Pharmaceuticals Ltd have entered

into the Revenue Sharing Agreement in respect to ponesimod. Under the terms of

the Revenue Sharing Agreement, Idorsia Pharmaceuticals Ltd is entitled to

receive quarterly payments of 8% of the net sales of ponesimod products from

Actelion Pharmaceuticals Ltd.

 

* Aubagio ® is a registered trademark of Sanofi Société Anonyme France.

 

Notes to the editor

 

About Idorsia

Idorsia Ltd is reaching out for more - We have more ideas, we see more

opportunities and we want to help more patients. In order to achieve this, we

will develop Idorsia into one of Europe’s leading biopharmaceutical companies,

with a strong scientific core.

 

Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is

specialized in the discovery and development of small molecules, to transform

the horizon of therapeutic options. Idorsia has a broad portfolio of innovative

drugs in the pipeline, an experienced team, a fully-functional research center,

and a strong balance sheet – the ideal constellation to bringing R&D efforts to

business success.

 

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June

2017 and has over 750 highly qualified specialists dedicated to realizing our

ambitious targets.

 

For further information, please contact

Andrew C. Weiss

Senior Vice President, Head of Investor Relations & Corporate Communications

Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil

+41 (0) 58 844 10 10

www.idorsia.com

 

The above information contains certain 'forward-looking statements', relating

to the company's business, which can be identified by the use of

forward-looking terminology such as 'estimates', 'believes', 'expects', 'may',

'are expected to', 'will', 'will continue', 'should', 'would be', 'seeks',

'pending' or 'anticipates' or similar expressions, or by discussions of

strategy, plans or intentions. Such statements include descriptions of the

company's investment and research and development programs and anticipated

expenditures in connection therewith, descriptions of new products expected to

be introduced by the company and anticipated customer demand for such products

and products in the company's existing portfolio. Such statements reflect the

current views of the company with respect to future events and are subject to

certain risks, uncertainties and assumptions. Many factors could cause the

actual results, performance or achievements of the company to be materially

different from any future results, performances or achievements that may be

expressed or implied by such forward-looking statements. Should one or more of

these risks or uncertainties materialize, or should underlying assumptions

prove incorrect, actual results may vary materially from those described herein

as anticipated, believed, estimated or expected.

 

 

 

Anhang Medienmitteilung PDF

Newsletter

 

Subscribe to our free newsletter and you will receive the latest information about our products and solutions.